The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482 · see citing works

The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors

Kawai, T., & Akira, S. (2010) · Nature Immunology · doi:10.1038/ni.1863 · Cited by 9,304 · see citing works

Age-related clonal hematopoiesis associated with adverse outcomes

Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841 · see citing works

International scoring system for evaluating prognosis in myelodysplastic syndromes

Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427 · see citing works

NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses

Taganov, K. D., Boldin, M. P., Chang, K.-J., & Baltimore, D. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605298103 · Cited by 4,317 · see citing works

Toll-like receptor control of the adaptive immune responses

Iwasaki, A., & Medzhitov, R. M. (2004) · Nature Immunology · doi:10.1038/ni1112 · Cited by 4,166 · see citing works

Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence

Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531 · see citing works

Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores

Liu, X., Zhang, Z., Ruan, J., Pan, Y., Magupalli, V. G., Wu, H., & Lieberman, J. (2016) · Nature · doi:10.1038/nature18629 · Cited by 3,202 · see citing works

Pyroptosis: host cell death and inflammation

Bergsbaken, T., Fink, S. L., & Cookson, B. T. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2070 · Cited by 3,185 · see citing works

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G. F., Garcia‐Manero, G., Solé, F. G., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., et al. (2012) · Blood · doi:10.1182/blood-2012-03-420489 · Cited by 3,181 · see citing works

A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases

Coll, R. C., Robertson, A. A. B., Chae, J. J., Higgins, S. C., Muñoz-Planillo, R., Inserra, M. C., Vetter, I., Dungan, L. S., Monks, B. G., Stutz, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3806 · Cited by 2,849 · see citing works

Pore-forming activity and structural autoinhibition of the gasdermin family

Ding, J., Wang, K., Liu, W., She, Y., Sun, Q., Shi, J., Sun, H., Wang, D.-C., & Shao, F. (2016) · Nature · doi:10.1038/nature18590 · Cited by 2,771 · see citing works

Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease

Jaiswal, S., Natarajan, P., Silver, A. J., Gibson, C. J., Bick, A. G., Shvartz, E., McConkey, M., Gupta, N., Gabriel, S., Ardissino, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701719 · Cited by 2,683 · see citing works

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Fenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70003-8 · Cited by 2,663 · see citing works

Targeting the NLRP3 inflammasome in inflammatory diseases

Mangan, M. S. J., Olhava, E. J., Roush, W. R., Seidel, H. M., Glick, G. D., & Latz, E. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.97 · Cited by 1,885 · see citing works

Age-related mutations associated with clonal hematopoietic expansion and malignancies

Xie, M., Lu, C., Wang, J., McLellan, M. D., Johnson, K. J., Wendl, M. C., McMichael, J. F., Schmidt, H. K., Yellapantula, V., Miller, C. A., et al. (2014) · Nature Medicine · doi:10.1038/nm.3733 · Cited by 1,874 · see citing works

Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases

Dinarello, C., Simon, A., & van der Meer, J. V. D. (2012) · Nature reviews. Drug discovery · doi:10.1038/nrd3800 · Cited by 1,813 · see citing works

Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice

Fuster, J. J., MacLauchlan, S., Zuriaga, M. A., Polackal, M. N., Ostriker, A. C., Chakraborty, R., Wu, C.-L., Sano, S., Muralidharan, S., Rius, C., et al. (2017) · Science · doi:10.1126/science.aag1381 · Cited by 1,536 · see citing works

Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock

Vogl, T., Tenbrock, K., Ludwig, S., Leukert, N., Ehrhardt, C., van Zoelen, M. A. D., Nacken, W., Foell, D., van der Poll, T., Sorg, C., et al. (2007) · Nature Medicine · doi:10.1038/nm1638 · Cited by 1,418 · see citing works

Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

Ridker, P. M., MacFadyen, J. G., Thuren, T., Everett, B. M., Libby, P., Glynn, R. J., Ridker, P., Lorenzatti, A., Krum, H., Varigos, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32247-x · Cited by 1,344 · see citing works

Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion

List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., Powell, B., Greenberg, P., Thomas, D., Stone, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061292 · Cited by 1,319 · see citing works

NF-κB Restricts Inflammasome Activation via Elimination of Damaged Mitochondria

Zhong, Z., Umemura, A., Sanchez-Lopez, E., Liang, S., Shalapour, S., Wong, J., He, F., Boassa, D., Perkins, G., Ali, S. R., et al. (2016) · Cell · doi:10.1016/j.cell.2015.12.057 · Cited by 1,197 · see citing works

GSDMD membrane pore formation constitutes the mechanism of pyroptotic cell death

Sborgi, L., Rühl, S., Mulvihill, E., Pipercevic, J., Heilig, R., Stahlberg, H., Farady, C. J., Müller, D. J., Broz, P., & Hiller, S. (2016) · The EMBO Journal · doi:10.15252/embj.201694696 · Cited by 1,152 · see citing works

Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia

Raaijmakers, M. H. G. P., Mukherjee, S., Guo, S., Zhang, S., Kobayashi, T., Schoonmaker, J. A., Ebert, B. L., Al-Shahrour, F., Hasserjian, R. P., Scadden, E. O., et al. (2010) · Nature · doi:10.1038/nature08851 · Cited by 1,115 · see citing works

IL-1 is required for tumor invasiveness and angiogenesis

Voronov, E., Shouval, D. S., Krelin, Y., Cagnano, E., Benharroch, D., Iwakura, Y., Dinarello, C. A., & Apte, R. N. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0437939100 · Cited by 1,023 · see citing works

Type I Interferon Inhibits Interleukin-1 Production and Inflammasome Activation

Guarda, G., Braun, M., Staehli, F., Tardivel, A., Mattmann, C., Förster, I., Farlik, M., Decker, T., Pasquier, R. D., Romero, P. J., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.02.006 · Cited by 924 · see citing works

GsdmD p30 elicited by caspase-11 during pyroptosis forms pores in membranes

Aglietti, R. A., Estevez, A., Gupta, A., Ramirez, M. G., Liu, P. S., Kayagaki, N., Ciferri, C., Dixit, V. M., & Dueber, E. C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1607769113 · Cited by 898 · see citing works

The endogenous Toll–like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer

Ehrchen, J. M., Sunderkötter, C. H., Foell, D., Vogl, T., & Roth, J. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.1008647 · Cited by 848 · see citing works

Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6

Zhang, Q., Zhao, K., Shen, Q., Han, Y., Gu, Y., Li, X., Zhao, D., Liu, Y., Wang, C., Zhang, X., et al. (2015) · Nature · doi:10.1038/nature15252 · Cited by 807 · see citing works

Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly

Zink, F., Stacey, S. N., Norddahl, G. L., Frigge, M. L., Magnusson, O. T., Jonsdottir, I., Thorgeirsson, T. E., Sigurdsson, A., Gudjonsson, S. A., Gudmundsson, J., et al. (2017) · Blood · doi:10.1182/blood-2017-02-769869 · Cited by 777 · see citing works

The adaptor ASC has extracellular and 'prionoid' activities that propagate inflammation

Franklin, B. S., Bossaller, L., De Nardo, D., Ratter, J. M., Stutz, A., Engels, G., Brenker, C., Nordhoff, M., Mirandola, S. R., Al-Amoudi, A., et al. (2014) · Nature Immunology · doi:10.1038/ni.2913 · Cited by 773 · see citing works

Proinflammatory S100 Proteins Regulate the Accumulation of Myeloid-Derived Suppressor Cells

Sinha, P., Okoro, C., Foell, D., Freeze, H. H., Ostrand‐Rosenberg, S., & Srikrishna, G. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.7.4666 · Cited by 722 · see citing works

Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression.

Bunt, S. K., Yang, L.-L., Sinha, P., Clements, V., Leips, J., & Ostrand-Rosenberg, S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2354 · Cited by 680 · see citing works

Identification of miR-145 and miR-146a as mediators of the 5q– syndrome phenotype

Starczynowski, D. T., Kuchenbauer, F. C., Argiropoulos, B., Sung, S., Morin, R. D., Muranyi, A., Hirst, M., Hogge, D. E., Marra, M. A., Wells, R. A., et al. (2009) · Nature Medicine · doi:10.1038/nm.2054 · Cited by 655 · see citing works

Somatic mutations precede acute myeloid leukemia years before diagnosis

Desai, P., Mencia-Trinchant, N., Savenkov, O., Simon, M. S., Cheang, G., Lee, S., Samuel, M., Ritchie, E. K., Guzman, M. L., Ballman, K. V., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0081-z · Cited by 619 · see citing works

Inflammation Induces Myeloid-Derived Suppressor Cells that Facilitate Tumor Progression

Bunt, S. K., Sinha, P., Clements, V. K., Leips, J., & Ostrand‐Rosenberg, S. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.284 · Cited by 539 · see citing works

Erratum: Targeting the NLRP3 inflammasome in inflammatory diseases

Mangan, M. S. J., Olhava, E. J., Roush, W. R., Seidel, H. M., Glick, G. D., & Latz, E. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.149 · Cited by 465 · see citing works

Bruton’s tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury

Ito, M., Shichita, T., Okada, M., Komine, R., Noguchi, Y., Yoshimura, A., & Morita, R. (2015) · Nature Communications · doi:10.1038/ncomms8360 · Cited by 417 · see citing works

ASC filament formation serves as a signal amplification mechanism for inflammasomes

Dick, M. S., Sborgi, L., Rühl, S., Hiller, S., & Brož, P. (2016) · Nature Communications · doi:10.1038/ncomms11929 · Cited by 405 · see citing works

Pyroptosis triggers pore-induced intracellular traps (PITs) that capture bacteria and lead to their clearance by efferocytosis

Jorgensen, I., Zhang, Y., Krantz, B. A., & Miao, E. A. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20151613 · Cited by 403 · see citing works

The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype

Basiorka, A. A., McGraw, K. L., Eksioglu, E. A., Chen, X., Johnson, J., Zhang, L., Zhang, Q., Irvine, B. A., Cluzeau, T., Sallman, D. A., et al. (2016) · Blood · doi:10.1182/blood-2016-07-730556 · Cited by 356 · see citing works

Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins

Lee, S. C.-W., Dvinge, H., Kim, E. H., Cho, H., Micol, J., Chung, Y. R., Durham, B. H., Yoshimi, A., Kim, Y. J., Thomas, M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4097 · Cited by 347 · see citing works

Mesenchymal inflammation drives genotoxic stress in hematopoietic stem cells and predicts disease evolution in human pre-leukemia

Zambetti, N. A., Ping, Z., Chen, S., Kenswil, K. J. G., Mylona, M. A., Sanders, M. A., Hoogenboezem, R. M., Bindels, E. M. J., Adisty, M. N., Van Strien, P. M. H., et al. (2016) · Cell stem cell · doi:10.1016/j.stem.2016.08.021 · Cited by 342 · see citing works

Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo

Abdel-Wahab, O. I., Gao, J., Adli, M., Dey, A., Trimarchi, T., Chung, Y. R., Kuscu, C., Hricik, T., Ndiaye‐Lobry, D., LaFave, L. M., et al. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20131141 · Cited by 322 · see citing works

Induction of myelodysplasia by myeloid-derived suppressor cells

Chen, X., Eksioglu, E. A., Zhou, J., Zhang, L., Djeu, J., Fortenbery, N., Epling-Burnette, P., Van Bijnen, S., Dolstra, H., Cannon, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67580 · Cited by 316 · see citing works

MCC950, a specific small molecule inhibitor of NLRP3 inflammasome attenuates colonic inflammation in spontaneous colitis mice

Perera, A. P., Fernando, R., Shinde, T., Gundamaraju, R., Southam, B., Sohal, S. S., Robertson, A. A. B., Schroder, K., Kunde, D., & Eri, R. D. (2018) · Scientific Reports · doi:10.1038/s41598-018-26775-w · Cited by 300 · see citing works

The Augmented R-Loop Is a Unifying Mechanism for Myelodysplastic Syndromes Induced by High-Risk Splicing Factor Mutations

Chen, L., Chen, J., Huang, Y.-J., Gu, Y., Qiu, J., Qian, H., Shao, C., Zhang, X., Hu, J., Li, H., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2017.12.029 · Cited by 295 · see citing works

Chronic Immune Stimulation Might Act As a Trigger for the Development of Acute Myeloid Leukemia or Myelodysplastic Syndromes

Kristinsson, S. Y., Björkholm, M., Hultcrantz, M. L., Derolf, Å. R., Landgren, O., & Goldin, L. R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.8540 · Cited by 288 · see citing works

S100A8 and S100A9 Induce Cytokine Expression and Regulate the NLRP3 Inflammasome via ROS-Dependent Activation of NF-κB1

Simard, J.-C., Césaro, A., Chapeton-Montes, J. A., Tardif, M. R., Antoine, F., Girard, D., & Tessier, P. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072138 · Cited by 263 · see citing works

Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes

Gañán-Gómez, I., Wei, Y., Starczynowski, D. T., Colla, S., Yang, H., Cabrero-Calvo, M., Bohannan, Z. S., Verma, A., Steidl, U., & Garcia-Manero, G. (2015) · Leukemia · doi:10.1038/leu.2015.69 · Cited by 236 · see citing works

Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9

Schneider, R. K., Schenone, M., Ferreira, M. S. V., Kramann, R., Joyce, C. E., Hartigan, C. R., Beier, F., Brümmendorf, T. H., Germing, U., Platzbecker, U., et al. (2016) · Nature Medicine · doi:10.1038/nm.4047 · Cited by 236 · see citing works

Chronic immune response dysregulation in MDS pathogenesis

Barreyro, L., Chlon, T. M., & Starczynowski, D. T. (2018) · Blood · doi:10.1182/blood-2018-03-784116 · Cited by 226 · see citing works

Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations

Lee, S. C.-W., North, K., Kim, E., Jang, E., Obeng, E., Lu, S. X., Liu, B., Inoue, D., Yoshimi, A., Ki, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.07.003 · Cited by 219 · see citing works

Methyltransferase Dnmt3a upregulates HDAC9 to deacetylate the kinase TBK1 for activation of antiviral innate immunity

Li, X., Zhang, Q., Ding, Y., Liu, Y., Zhao, D., Zhao, K., Shen, Q., Liu, X., Zhu, X., Li, N., et al. (2016) · Nature Immunology · doi:10.1038/ni.3464 · Cited by 202 · see citing works

Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome

Rhyasen, G. W., Bolanos, L., Fang, J., Jerez, A., Wunderlich, M., Rigolino, C., Mathews, L., Ferrer, M., Southall, N., Guha, R., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.05.006 · Cited by 199 · see citing works

Alarmin S100A8/S100A9 as a biomarker for molecular imaging of local inflammatory activity

Vogl, T., Eisenblätter, M., Völler, T., Zenker, S., Hermann, S., van Lent, P., Faust, A., Geyer, C., Petersen, B., Roebrock, K., et al. (2014) · Nature Communications · doi:10.1038/ncomms5593 · Cited by 193 · see citing works

The structure of rotational bands in alpha-cluster nuclei

Bijker, R. (2015) · EPJ Web of Conferences · doi:10.1051/epjconf/20159301011 · Cited by 184 · see citing works

Toll-like receptor alterations in myelodysplastic syndrome

Wei, Y., Dimicoli, S., Bueso‐Ramos, C. E., Chen, R., Yang, H., Neuberg, D. S., Pierce, S. A., Jia, Y., Zheng, H., Wang, H., et al. (2013) · Leukemia · doi:10.1038/leu.2013.180 · Cited by 159 · see citing works

Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines.

Raza (1996) · International Journal of Hematology · doi:10.1016/0925-5710(96)00455-0 · Cited by 141 · see citing works

Toll-like Receptor-4 Is Up-Regulated in Hematopoietic Progenitor Cells and Contributes to Increased Apoptosis in Myelodysplastic Syndromes

Maratheftis, C. I., Andreakos, E., Moutsopoulos, H. Μ., & Voulgarelis, M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2108 · Cited by 139 · see citing works

Human NACHT, LRR, and PYD domain–containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase

Liu, X., Pichulik, T., Wolz, O., Dang, T., Stutz, A., Dillen, C. A., Garcia, M. D., Kraus, H., Dickhöfer, S., Daiber, E., et al. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.01.017 · Cited by 132 · see citing works

U2AF35(S34F) Promotes Transformation by Directing Aberrant ATG7 Pre-mRNA 3′ End Formation

Park, S. M., Ou, J., Chamberlain, L., Simone, T. M., Yang, H., Virbasius, C.-M. A., Ali, A. M., Zhu, L. J., Mukherjee, S., Raza, A., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.04.011 · Cited by 131 · see citing works

Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype

Sallman, D. A., Cluzeau, T., Basiorka, A. A., & List, A. F. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00151 · Cited by 115 · see citing works

Loss of Tifab, a del(5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptor–TRAF6 signaling

Varney, M. E., Niederkorn, M., Konno, H., Matsumura, T., Gohda, J., Yoshida, N., Akiyama, T., Christie, S., Fang, J., Miller, D., et al. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20141898 · Cited by 111 · see citing works

Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1

Fang, J., Rhyasen, G. W., Bolanos, L. C., Rasch, C., Varney, M. E., Wunderlich, M., Goyama, S., Jansen, G., Cloos, J. J., Rigolino, C., et al. (2012) · Blood · doi:10.1182/blood-2012-02-407999 · Cited by 106 · see citing works

Hyperactive mTOR pathway promotes lymphoproliferation and abnormal differentiation in autoimmune lymphoproliferative syndrome

Völkl, S., Rensing‐Ehl, A., Allgäuer, A., Schreiner, E., Lorenz, M. R., Rohr, J., Klemann, C., Fuchs, I., Schuster, V. H., von Bueren, A. O., et al. (2016) · Blood · doi:10.1182/blood-2015-11-685024 · Cited by 98 · see citing works

Reduction in C‐reactive protein indicates successful targeting of the IL‐1/IL‐6 axis resulting in improved survival in early stage multiple myeloma

Lust, J. A., Lacy, M. Q., Zeldenrust, S. R., Witzig, T. E., Moon‐Tasson, L. L., Dinarello, C. A., & Donovan, K. A. (2016) · American Journal of Hematology · doi:10.1002/ajh.24352 · Cited by 92 · see citing works

Interleukin‐1 in multiple myeloma: producer cells and their role in the control of IL‐6 production

Costes, V., Portier, M., Lu, Z.-Y., Rossi, J., Bataille, R., & Klein, B. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.01101.x · Cited by 88 · see citing works

Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells

Wei, Y., Chen, R., Dimicoli, S., Bueso‐Ramos, C. E., Neuberg, D. S., Pierce, S. A., Wang, H., Yang, H., Jia, Y., Zheng, H., et al. (2013) · Leukemia · doi:10.1038/leu.2013.91 · Cited by 83 · see citing works

S-adenosylhomocysteine induces inflammation through NFkB: A possible role for EZH2 in endothelial cell activation

Barroso, M., Kao, D. D., Blom, H. J., de Almeida, I. T., Castro, R., Loscalzo, J., & Handy, D. E. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.10.019 · Cited by 82 · see citing works

Age-related inflammatory bone marrow microenvironment induces ineffective erythropoiesis mimicking del(5q) MDS

Mei, Y., Zhao, B., Basiorka, A. A., Yang, J. C., Cao, L., Zhang, J., List, A. F., & Ji, P. (2017) · Leukemia · doi:10.1038/leu.2017.326 · Cited by 72 · see citing works

Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858

Eksioglu, E. A., Chen, X., Heider, K.-H., Rueter, B., McGraw, K. L., Basiorka, A. A., Wei, M., Burnette, A., Cheng, P., Lancet, J., et al. (2017) · Leukemia · doi:10.1038/leu.2017.21 · Cited by 66 · see citing works

Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study

Basiorka, A. A., McGraw, K. L., Aghababazadeh, F. A., McLemore, A. F., Vincelette, N. D., Ward, G., Eksioglu, E. A., Sallman, D. A., Ali, N. E. A., Padron, E., et al. (2018) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30109-1 · Cited by 60 · see citing works

Circulating S100A8 and S100A9 protein levels in plasma of patients with acquired aplastic anemia and myelodysplastic syndromes

Giudice, V., Wu, Z., Kajigaya, S., Ibanez, M. D. P. F., Rios, O. J., Cheung, F., Ito, S., & Young, N. S. (2018) · Cytokine · doi:10.1016/j.cyto.2018.06.025 · Cited by 51 · see citing works

Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes

Cluzeau, T., McGraw, K. L., Irvine, B. A., Masala, E., Adès, L., Basiorka, A. A., Maciejewski, J. P., Auberger, P., Wei, S., Fenaux, P., et al. (2017) · Haematologica · doi:10.3324/haematol.2016.158857 · Cited by 49 · see citing works

KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice

Wei, Y., Zheng, H., Bao, N., Jiang, S., Bueso-Ramos, C., Khoury, J. D., Class, C. A., Lu, Y., Lin, K., Yang, H., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018024166 · Cited by 42 · see citing works

TET1 is a negative transcriptional regulator of IL-1β in the THP-1 cell line

Neves‐Costa, A., & Moita, L. F. (2013) · Molecular Immunology · doi:10.1016/j.molimm.2012.12.014 · Cited by 38 · see citing works

Apoptosis in human myelodysplastic syndrome CD34+ cells is modulated by the upregulation of TLRs and histone H4 acetylation via a β-arrestin 1 dependent mechanism

Zeng, Q., Shu, J. S., Hu, Q., Shao-hong, Z., Qian, Y., Hu, M., Hu, L., Wang, Y., Zhou, Y., & Lü, J. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.12.008 · Cited by 28 · see citing works

An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes

Daher, M., Lopez, J. E. H., Randhawa, J. K., Jabbar, K. J., Wei, Y., Pemmaraju, N., Borthakur, G. M., Kadia, T. M., Konopleva, M. Y., Kantarjian, H. M., et al. (2017) · American Journal of Hematology · doi:10.1002/ajh.24746 · Cited by 26 · see citing works

A Clinical Study of OPN-305, a Toll-like Receptor 2 (TLR-2) Antibody, in Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received Prior Hypomethylating Agent (HMA) Therapy

Garcia‐Manero, G., Bravo, G. M., Yang, H., Wei, Y., Alvarado, Y., Dinardo, C. D., Daver, N. G., Konopleva, M. Y., Hearn, K. P., Miller, R. M., et al. (2016) · Blood · doi:10.1182/blood.v128.22.227.227 · Cited by 23 · see citing works

SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes

Sallman, D. A., Tanaka, T. N., List, A. F., & Bejar, R. L. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.09.018 · Cited by 11 · see citing works

Inflammation as a regulator of hematopoietic stem cell function in disease, aging, and clonal selection

Caiado, F., Pietras, E. M., & Manz, M. G. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201541 · Cited by 289 · see citing works

Inflammation-Induced Tumorigenesis and Metastasis

Hibino, S., Kawazoe, T., Kasahara, H., Itoh, S., Ishimoto, T., Sakata‐Yanagimoto, M., & Taniguchi, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115421 · Cited by 303 · see citing works

Hallmarks of ribosomopathies

Kampen, K. R., Sulima, S. O., Vereecke, S., & Keersmaecker, K. D. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz637 · Cited by 217 · see citing works

Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS

Trowbridge, J. J., & Starczynowski, D. T. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201544 · Cited by 189 · see citing works

Pharmacological Inhibition of the Nod-Like Receptor Family Pyrin Domain Containing 3 Inflammasome with MCC950

Corcoran, S. E., Halai, R., & Cooper, M. A. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000171 · Cited by 179 · see citing works

S100A8 and S100A9 in Cancer

Chen, Y., Ouyang, Y., Li, Z., Wang, X., & Ma, J. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188891 · Cited by 165 · see citing works

ER Stress Activates the NLRP3 Inflammasome: A Novel Mechanism of Atherosclerosis

Chen, X., Guo, X.-C., Ge, Q., Zhao, Y., Mu, H., & Zhang, J. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/3462530 · Cited by 132 · see citing works

Clonal hematopoiesis and inflammation: Partners in leukemogenesis and comorbidity

Cook, E. K., Luo, M., & Rauh, M. J. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.01.011 · Cited by 121 · see citing works

Current challenges and unmet medical needs in myelodysplastic syndromes

Platzbecker, U., Kubasch, A. S., Homer-Bouthiette, C., & Prébet, T. (2021) · Leukemia · doi:10.1038/s41375-021-01265-7 · Cited by 102 · see citing works

IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies

Bennett, J., & Starczynowski, D. T. (2021) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000693 · Cited by 100 · see citing works

Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia

Yang, X., Ma, L., Zhang, X., Huang, L., & Wei, J. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00263-4 · Cited by 98 · see citing works

Clonal hematopoiesis in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis

Arends, C. M., Weiß, M., Christen, F., Eulenberg-Gustavus, C., Rousselle, A., Kettritz, R., Eckardt, K., Chan, W., Hoyer, K., Frick, M., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.223305 · Cited by 87 · see citing works

Inflammatory bone marrow microenvironment

Leimkühler, N. B., & Schneider, R. K. (2019) · Hematology · doi:10.1182/hematology.2019000045 · Cited by 82 · see citing works

Integrating the “Immunome” in the Stratification of Myelodysplastic Syndromes and Future Clinical Trial Design

Winter, S., Shoaie, S., Kordasti, S. Y., & Platzbecker, U. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01823 · Cited by 82 · see citing works

Involvement of inflammasomes in tumor microenvironment and tumor therapies

Zhang, Z., Li, X., Wang, Y., Wei, Y., & Wei, X. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01407-7 · Cited by 79 · see citing works

EASIX for prediction of survival in lower-risk myelodysplastic syndromes

Merz, A. M. A., Germing, U., Kobbe, G., Kaivers, J., Jauch, A. S., Radujkovic, A., Hummel, M., Benner, A., Merz, M., Dreger, P., et al. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0247-z · Cited by 76 · see citing works

Sequential CRISPR gene editing in human iPSCs charts the clonal evolution of myeloid leukemia and identifies early disease targets

Wang, T., Pine, A. R., Kotini, A. G., Yuan, H., Zamparo, L., Starczynowski, D. T., Leslie, C. S., & Papapetrou, E. P. (2021) · Cell stem cell · doi:10.1016/j.stem.2021.01.011 · Cited by 76 · see citing works

Current and emerging strategies for management of myelodysplastic syndromes

Saygin, C., & Carraway, H. E. (2021) · Blood Reviews · doi:10.1016/j.blre.2020.100791 · Cited by 70 · see citing works

Cellular senescence induced by S100A9 in mesenchymal stromal cells through NLRP3 inflammasome activation

Shi, L., Zhao, Y., Fei, C., Guo, J., Jia, Y., Wu, D., Wu, L., & Chang, C. (2019) · Aging · doi:10.18632/aging.102409 · Cited by 68 · see citing works

TRAF6 functions as a tumor suppressor in myeloid malignancies by directly targeting MYC oncogenic activity

Muto, T., Guillamot, M., Yeung, J., Fang, J., Bennett, J. R., Nadorp, B., Lasry, A., Zea-Redondo, L., Choi, K., Gong, Y., et al. (2022) · Cell stem cell · doi:10.1016/j.stem.2021.12.007 · Cited by 57 · see citing works

Inflammation, Aging and Hematopoiesis: A Complex Relationship

Bousounis, P., Bergo, V., & Trompouki, E. (2021) · Cells · doi:10.3390/cells10061386 · Cited by 58 · see citing works

Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease

Zhao, L., Boy, M., Azoulay, C., Clappier, E., Sébert, M., Amable, L., Klibi, J., Benlagha, K., Espéli, M., Balabanian, K., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01152-1 · Cited by 59 · see citing works

Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AML

Bennett, J. R., Ishikawa, C., Agarwal, P., Yeung, J., Sampson, A. M., Uible, E. E., Vick, E. J., Bolanos, L. C., Hueneman, K. M., Wunderlich, M., et al. (2023) · Blood · doi:10.1182/blood.2022018718 · Cited by 56 · see citing works

Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues

Porwit‐MacDonald, A., Béné, M. C., Duetz, C., Matarraz, S., Oelschlaegel, U., Westers, T. M., Wagner‐Ballon, O., Kordasti, S. Y., Valent, P., Preijers, F. W. M. B., et al. (2022) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.22108 · Cited by 54 · see citing works

Iron overload-induced oxidative stress in myelodysplastic syndromes and its cellular sequelae

Kim, C. H., & Leitch, H. A. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103367 · Cited by 54 · see citing works

Flaming and fanning: The Spectrum of inflammatory influences in myelodysplastic syndromes

Banerjee, T., Calvi, L. M., Becker, M. W., & Liesveld, J. L. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.04.004 · Cited by 51 · see citing works

Contribution of Aberrant Toll Like Receptor Signaling to the Pathogenesis of Myelodysplastic Syndromes

Paracatu, L. C., & Schuettpelz, L. G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01236 · Cited by 50 · see citing works

Inflammation and myeloid malignancy: quenching the flame

Stubbins, R. J., Platzbecker, U., & Karsan, A. (2022) · Blood · doi:10.1182/blood.2021015162 · Cited by 46 · see citing works

Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes

Kouroukli, O., Symeonidis, A. S., Foukas, P. G., Maragkou, M., & Kourea, E. P. (2022) · Cancers · doi:10.3390/cancers14225656 · Cited by 48 · see citing works

The roles of bone remodeling in normal hematopoiesis and age-related hematological malignancies

Zhang, H., Liesveld, J. L., Calvi, L. M., Lipe, B. C., Xing, L., Becker, M. W., Schwarz, E. M., & Yeh, S.-C. A. (2023) · Bone Research · doi:10.1038/s41413-023-00249-w · Cited by 46 · see citing works

TIM3 / CEACAM1 pathway involves in myeloid‐derived suppressor cells induced CD8 + T cells exhaustion and bone marrow inflammatory microenvironment in myelodysplastic syndrome

Yu, S., Ren, X., Meng, F., Guo, X., Tao, J., Zhang, W., Liu, Z., Fu, R., & Li, L. (2022) · Immunology · doi:10.1111/imm.13488 · Cited by 43 · see citing works

Clonal Hematopoiesis, Inflammation, and Hematologic Malignancy

Kanagal‐Shamanna, R., Beck, D. B., & Calvo, K. R. (2023) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-051222-122724 · Cited by 42 · see citing works

Myeloid-Derived Suppressor Cells and Mesenchymal Stem/Stromal Cells in Myeloid Malignancies

Kapor, S., & Santibanez, J. F. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132788 · Cited by 40 · see citing works

Unknown/enigmatic functions of extracellular ASC

de Souza, J. G., Starobinas, N., & Ibañez, O. M. (2021) · Immunology · doi:10.1111/imm.13375 · Cited by 39 · see citing works

Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin

Yu, S., Ren, X., & Li, L. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00296-9 · Cited by 40 · see citing works

Mitochondrial transplantation confers protection against the effects of ischemic stroke by repressing microglial pyroptosis and promoting neurogenesis

Sun, L., Zhao, Z., Guo, J., Qin, Y., Yu, Q., Shi, X., Guo, F., Zhang, H., Sun, X., Gao, C., et al. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.385313 · Cited by 37 · see citing works

Therapeutic targeting of the inflammasome in myeloid malignancies

Chakraborty, S., Shapiro, L. C., de Oliveira, S., Rivera-Peña, B., Verma, A. K., & Shastri, A. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00547-8 · Cited by 40 · see citing works

T-cell dysfunctions in myelodysplastic syndromes

Rodríguez‐Sevilla, J. J., & Colla, S. (2024) · Blood · doi:10.1182/blood.2023023166 · Cited by 37 · see citing works

Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome

Lee, P., Yim, R., Yung, Y., Chu, H.-T., Yip, P.-K., & Gill, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910232 · Cited by 38 · see citing works

Management of patients with lower-risk myelodysplastic syndromes

Brunner, A. M., Leitch, H. A., van de Loosdrecht, A. A., & Bonadies, N. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00765-8 · Cited by 37 · see citing works

IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies

Parrondo, R. D., Iqbal, M., von Roemeling, R., Roemeling, C. A. V., & Tun, H. W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1239082 · Cited by 36 · see citing works

Mechanism and role of regulated cell death in tumor immunity and immunotherapy

Hu, J., Li, Y., Lian, B., Mao, Y., & Zhao, L. (2025) · 癌症：英文版 · doi:10.1002/cac2.70064 · Cited by 38 · see citing works

Mitochondrial Fragmentation Triggers Ineffective Hematopoiesis in Myelodysplastic Syndromes

Aoyagi, Y., Hayashi, Y., Harada, Y., Choi, K., Matsunuma, N., Sadato, D., Maemoto, Y., Ito, A., Yanagi, S., Starczynowski, D. T., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0032 · Cited by 35 · see citing works

Thromboinflammation in Myeloproliferative Neoplasms (MPN)—A Puzzle Still to Be Solved

Bhuria, V., Baldauf, C. K., Schraven, B. L., & Fischer, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063206 · Cited by 38 · see citing works

IL-1 in aging and pathologies of hematopoietic stem cells

Caiado, F., & Manz, M. G. (2024) · Blood · doi:10.1182/blood.2023023105 · Cited by 38 · see citing works

A CIBERSORTx-based immune cell scoring system could independently predict the prognosis of patients with myelodysplastic syndromes

Wang, Y., Hou, H., Lin, C., Kuo, Y., Yao, C., Hsu, C., Tseng, M., Tsai, C., Peng, Y., Kao, C., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005141 · Cited by 35 · see citing works

NPM1 ablation induces HSC aging and inflammation to develop myelodysplastic syndrome exacerbated by p53 loss

Morganti, C., Ito, K., Yanase, C., Verma, A. K., Teruya‐Feldstein, J., & Ito, K. (2022) · EMBO Reports · doi:10.15252/embr.202154262 · Cited by 33 · see citing works

60 Years of clonal hematopoiesis research: From X-chromosome inactivation studies to the identification of driver mutations

Ayachi, S., Buscarlet, M., & Busque, L. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.01.008 · Cited by 32 · see citing works

Role of reactive oxygen species in myelodysplastic syndromes

Jing, Q., Zhou, C., Zhang, J., Zhang, P., Wu, Y., Zhou, J., Tong, X., Li, Y., Du, J., & Wang, Y. (2024) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-024-00570-0 · Cited by 33 · see citing works

Activation of distinct inflammatory pathways in subgroups of LR-MDS

Schneider, M., Rolfs, C., Trumpp, M., Winter, S., Fischer, L., Richter, M., Menger, V., Nenoff, K., Grieb, N., Metzeler, K. H., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01949-2 · Cited by 31 · see citing works

Fate of Hematopoiesis During Aging. What Do We Really Know, and What are its Implications?

Broxmeyer, H. E., Liu, Y., Kapur, R., Orschell, C. M., Aljoufi, A., Ropa, J. P., Trinh, T. L. P., Burns, S. S., & Capitano, M. L. (2020) · Stem Cell Reviews and Reports · doi:10.1007/s12015-020-10065-y · Cited by 30 · see citing works

Suprabasin—A Review

Přibyl, M., Hodný, Z., & Kubíková, I. (2021) · Genes · doi:10.3390/genes12010108 · Cited by 30 · see citing works

Patterns of Aneuploidy and Signaling Consequences in Cancer

Zhakula-Kostadinova, N., & Taylor, A. M. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-0169 · Cited by 27 · see citing works

ETV6 germline mutations cause HDAC3/NCOR2 mislocalization and upregulation of interferon response genes

Fisher, M. H., Kirkpatrick, G. D., Stevens, B. M., Jones, C. L., Callaghan, M. U., Rajpurkar, M., Fulbright, J. M., Cooper, M. A., Rowley, J. W., Porter, C. C., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140332 · Cited by 30 · see citing works

Multi-hit TET2 mutations as a differential molecular signature of oligomonocytic and overt chronic myelomonocytic leukemia

García-Gisbert, N., Arenillas, L., Roman-Bravo, D., Rodríguez‐Sevilla, J. J., Fernández‐Rodríguez, C., Garcia-Ávila, S., Vélez, P., Gibert, J., Fernández‐Ibarrondo, L., Salar, A., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01733-8 · Cited by 28 · see citing works

Progress in the study of molecular mechanisms of cell pyroptosis in tumor therapy

Wang, D., & Wan, X. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110143 · Cited by 25 · see citing works

Immune Dysfunction, Cytokine Disruption, and Stromal Changes in Myelodysplastic Syndrome: A Review

Lynch, O. F., & Calvi, L. M. (2022) · Cells · doi:10.3390/cells11030580 · Cited by 26 · see citing works

Inflammasomes—New Contributors to Blood Diseases

Tomasik, J., & Basak, G. W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158129 · Cited by 24 · see citing works

Targeting regulated cell death pathways in acute myeloid leukemia

Garciaz, S., Miller, T. W., Collette, Y., & Vey, N. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2022.108 · Cited by 24 · see citing works

U2AF1 mutation promotes tumorigenicity through facilitating autophagy flux mediated by FOXO3a activation in myelodysplastic syndromes

Zhu, Y., Song, D., Guo, J., Jin, J., Tao, Y., Zhang, Z., Xu, F., He, Q., Li, X., Chang, C., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03573-3 · Cited by 23 · see citing works

The role of lipid peroxidation products and antioxidant enzymes in the pathogenesis of aseptic and purulent inflammation in cats

Rudenko, P. A., Vatnikov, Y. A., Engashev, S. V., Kvochko, A. N., Notina, E. A., Bykova, I. A., Kulikov, E. V., Rudenko, A., Petrukhina, O. A., & Руденко, В. Б. (2021) · Journal of Advanced Veterinary and Animal Research · doi:10.5455/javar.2021.h504 · Cited by 24 · see citing works

Impact of preexisting autoimmune disease on myelodysplastic syndromes outcomes: a population analysis

Herrera, D. A., Sparks, A. D., Singh, R., Alejos, D., Batra, A., Glushakow-Smith, S. G., Pradhan, K., Shastri, A., & Zakai, N. A. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023011050 · Cited by 22 · see citing works

Microenvironmental Features Driving Immune Evasion in Myelodysplastic Syndromes and Acute Myeloid Leukemia

Barakos, G. P., & Hatzimichael, E. C. (2022) · Diseases · doi:10.3390/diseases10020033 · Cited by 22 · see citing works

Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation

Rodríguez‐Sevilla, J. J., Ademà, V., Garcia‐Manero, G., & Colla, S. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100940 · Cited by 23 · see citing works

Megakaryocytes Are Regulators of the Tumor Microenvironment and Malignant Hematopoietic Progenitor Cells in Myelofibrosis

Varricchio, L., & Hoffman, R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.906698 · Cited by 21 · see citing works

The yin-yang of immunity: Immune dysregulation in myelodysplastic syndrome with different risk stratification

Peng, X., Zhu, X., Di, T., Tang, F., Guo, X., Liu, Y., Bai, J., Li, Y., Li, L., & Zhang, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.994053 · Cited by 21 · see citing works

Clonal hematopoiesis and inflammation: A review of mechanisms and clinical implications

Nathan, D. I., Dougherty, M. L., Bhatta, M., Mascarenhas, J. O., & Marcellino, B. K. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104187 · Cited by 21 · see citing works

MDS-associated SF3B1 mutations enhance proinflammatory gene expression in patient blast cells

Pollyea, D. A., Kim, H. M., Stevens, B. M., Lee, F. F.-Y., Harris, C., Hedin, B. R., Knapp, J. R., O’Connor, B. P., Jordan, C. T., Pietras, E. M., et al. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.6ab0520-318rr · Cited by 20 · see citing works

Inflammatory Cytokine Profiles Do Not Differ Between Patients With Idiopathic Cytopenias of Undetermined Significance and Myelodysplastic Syndromes

Nielsen, A. B., Hansen, J. W., Ørskov, A. D., Dimopoulos, K., Salem, M., Grigorian, M., Brüünsgaard, H., & Grønbæk, K. (2022) · HemaSphere · doi:10.1097/hs9.0000000000000713 · Cited by 19 · see citing works

Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)

Bewersdorf, J. P., Xie, Z., Bejar, R. L., Borate, U., Boultwood, J., Brunner, A. M., Buckstein, R. J., Carraway, H. E., Churpek, J. E., Daver, N. G., et al. (2023) · Blood Reviews · doi:10.1016/j.blre.2023.101072 · Cited by 20 · see citing works

The shape of low-concentration dose–response functions for benzene: implications for human health risk assessment

Cox, L. A., Ketelslegers, H. B., & Lewis, R. J. (2021) · Critical Reviews in Toxicology · doi:10.1080/10408444.2020.1860903 · Cited by 20 · see citing works

Myelodysplasia Syndrome, Clonal Hematopoiesis and Cardiovascular Disease

Veiga, C. B., Lawrence, E., Murphy, A. J., Herold, M. J., & Dragoljevic, D. (2021) · Cancers · doi:10.3390/cancers13081968 · Cited by 19 · see citing works

Bone Marrow Niches and Tumour Cells: Lights and Shadows of a Mutual Relationship

Granata, V., Crisafulli, L., Nastasi, C., Ficara, F., & Sobacchi, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.884024 · Cited by 19 · see citing works

Hematopoietic progenitor cell liabilities and alarmins S100A8/A9‐related inflammaging associate with frailty and predict poor cardiovascular outcomes in older adults

Bonora, B. M., Palano, M. T., Testa, G., Fadini, G. P., Sangalli, E., Madotto, F., Persico, G., Casciaro, F., Vono, R., Colpani, O., et al. (2022) · Aging Cell · doi:10.1111/acel.13545 · Cited by 18 · see citing works

Targeting inflammation in lower-risk MDS

Gonzalez‐Lugo, J. D., & Verma, A. K. (2022) · Hematology · doi:10.1182/hematology.2022000350 · Cited by 19 · see citing works

Hippo kinase loss contributes to del(20q) hematologic malignancies through chronic innate immune activation

Stoner, S. A., Yan, M., Liu, K. T. H., Arimoto, K., Shima, T., Wang, H., Johnson, D. T., Bejar, R. L., Jamieson, C. H. M., Guan, K., et al. (2019) · Blood · doi:10.1182/blood.2019000170 · Cited by 19 · see citing works

How I treat iron overload in adult MDS

Leitch, H. A., & Buckstein, R. J. (2024) · Blood · doi:10.1182/blood.2023022501 · Cited by 18 · see citing works

The wider perspective: twenty years of clinical trials in myelodysplastic syndromes

Duetz, C., Cucchi, D. G. J., Polak, T. B., Janssen, J. J. W. M., Ossenkoppele, G. J., Estey, E. H., & van de Loosdrecht, A. A. (2021) · British Journal of Haematology · doi:10.1111/bjh.17892 · Cited by 18 · see citing works

Caspase-3/NLRP3 signaling in the mesenchymal stromal niche regulates myeloid-biased hematopoiesis

Zhang, J., Chen, Y., Yin, D., Feng, F., An, Q., Liu, Z., An, N., Xu, J., Yi, J., Gu, S., et al. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02640-y · Cited by 17 · see citing works

NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy

Hurtado‐Navarro, L., Cuenca‐Zamora, E. J., Zamora, L., Bellosillo, B., Such, E., Soler‐Espejo, E., Martínez‐Banaclocha, H., Hernández‐Rivas, J. M., Marco, J., Martínez-Alarcón, L., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101329 · Cited by 17 · see citing works

cGLRs Join Their Cousins of Pattern Recognition Receptor Family to Regulate Immune Homeostasis

Kumar, V., & Stewart, J. H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031828 · Cited by 18 · see citing works

Research and clinical updates on IRAK4 and its roles in inflammation and malignancy: themes and highlights from the 1st symposium on IRAK4 in cancer

Garcia‐Manero, G., Platzbecker, U., Lim, K., Nowakowski, G. S., Abdel-Wahab, O. I., Kantarjian, H. M., Verma, A. K., & Starczynowski, D. T. (2024) · Frontiers in Hematology · doi:10.3389/frhem.2024.1339870 · Cited by 17 · see citing works

Clonal Hematopoiesis of Indeterminate Potential as a Novel Risk Factor for Donor-Derived Leukemia

Burns, S. S., & Kapur, R. (2020) · Stem Cell Reports · doi:10.1016/j.stemcr.2020.07.008 · Cited by 18 · see citing works

Inflammasomes and the Maintenance of Hematopoietic Homeostasis: New Perspectives and Opportunities

Yang, L., Hu, M., Lu, Y., Han, S., & Wang, J. (2021) · Molecules · doi:10.3390/molecules26020309 · Cited by 17 · see citing works

Autoimmune disorders associated with myelodysplastic syndromes: clinical, prognostic and therapeutic implications

Fozza, C., Murtas, A., Caocci, G., & Nasa, G. L. (2022) · Leukemia Research · doi:10.1016/j.leukres.2022.106856 · Cited by 16 · see citing works

Inflammatory profile of lower risk myelodysplastic syndromes

Topping, J., Taylor, A., Nadat, F., Crouch, S., Ibbotson, A., Čermák, J., Symeonidis, A. S., Tatic, A., Langemeijer, S. M. C., Hellström‐Lindberg, E., et al. (2024) · British Journal of Haematology · doi:10.1111/bjh.19530 · Cited by 16 · see citing works

Germline ETV6 mutation promotes inflammation and disrupts lymphoid development of early hematopoietic progenitors

Zhou, C., Uluisik, R. C., Rowley, J. W., David, C., Jones, C. L., Scharer, C. D., Noetzli, L. J., Fisher, M. H., Kirkpatrick, G. D., Bark, K., et al. (2022) · Experimental Hematology · doi:10.1016/j.exphem.2022.06.002 · Cited by 16 · see citing works

Cigarette smoke impairs the hematopoietic supportive property of mesenchymal stem cells via the production of reactive oxygen species and NLRP3 activation

Park, H. S., Lee, B., Chae, D., Yu, A., Park, J. H., Heo, J., Han, M. H., Cho, K., Lee, J. W., Jung, J., et al. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03731-2 · Cited by 15 · see citing works

Inflammasome Activation in Myeloid Malignancies—Friend or Foe?

Andina, N. D., Bonadies, N., & Allam, R. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.825611 · Cited by 15 · see citing works

High BM plasma S100A8/A9 is associated with a perturbed microenvironment and poor prognosis in myelodysplastic syndromes

Wang, Y., Lin, C., Yao, C., Amaral, F. M. R., Yu, S., Kao, C., Shih, P., Hou, H., Chou, W., & Tien, H. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022008958 · Cited by 14 · see citing works

Emerging Insights into Molecular Mechanisms of Inflammation in Myelodysplastic Syndromes

Vallelonga, V., Gandolfi, F., Ficara, F., Porta, M. G. D., & Ghisletti, S. (2023) · Biomedicines · doi:10.3390/biomedicines11102613 · Cited by 13 · see citing works

Dysregulated innate immune signaling cooperates with RUNX1 mutations to transform an MDS-like disease to AML

Barreyro, L., Sampson, A. M., Hueneman, K. M., Choi, K., Christie, S., Ramesh, V., Wyder, M. A., Wang, D., Pujato, M. A., Greis, K. D., et al. (2024) · iScience · doi:10.1016/j.isci.2024.109809 · Cited by 14 · see citing works

Role of macrophages and phagocytes in orchestrating normal and pathologic hematopoietic niches

Lévesque, J.-P., SUMMERS, K. M., Millard, S. M., Bisht, K., Winkler, I. G., & Pettit, A. R. (2021) · Experimental Hematology · doi:10.1016/j.exphem.2021.07.001 · Cited by 15 · see citing works

Immune checkpoints bone marrow expression as the predictor of clinical outcome in myelodysplastic syndrome

Tcvetkov, N., Gusak, A., Morozova, Е. V., Moiseev, I., Baykov, V., Barabanshikova, M. V., Lepik, K. V., Bakin, E. A., Vlasova, J. J., Osipova, A., et al. (2020) · Leukemia Research Reports · doi:10.1016/j.lrr.2020.100215 · Cited by 14 · see citing works

Caspase 8 deletion causes infection/inflammation-induced bone marrow failure and MDS-like disease in mice

Liu, S., Joshi, K., Zhang, L., Li, W., Mack, R. M., Runde, A. P., Hagen, P. A., Barton, K., Breslin, P., Ji, H., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06660-3 · Cited by 12 · see citing works

Chromatin modifier Hmga2 promotes adult hematopoietic stem cell function and blood regeneration in stress conditions

Kubota, S., Sun, Y., Morii, M., Bai, J., Ideue, T., Hirayama, M., Sorin, S., Eerdunduleng, Yokomizo-Nakano, T., Osato, M., et al. (2024) · EMBO Journal · doi:10.1038/s44318-024-00122-4 · Cited by 10 · see citing works

Is Myelodysplasia a Consequence of Normal Aging?

Heibl, S., Stauder, R., & Pfeilstöcker, M. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01136-5 · Cited by 13 · see citing works

Genetic barcoding systematically compares genes in del(5q) MDS and reveals a central role for CSNK1A1 in clonal expansion

Stalmann, U. S. A., Ticconi, F., Snoeren, I., Li, R.-H., Gleitz, H. F. E., Cowley, G., McConkey, M., Wong, A., Schmitz, S., Fuchs, S. N. R., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006061 · Cited by 10 · see citing works

Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS

Frumm, S. M., Shimony, S. O., Stone, R. M., DeAngelo, D. J., Bewersdorf, J. P., Zeidan, A. M., & Stahl, M. F. (2023) · Blood Reviews · doi:10.1016/j.blre.2023.101056 · Cited by 12 · see citing works

ERVs-TLR3-IRF axis is linked to myelodysplastic syndrome pathogenesis

de Oliveira, R. T. G., Cordeiro, J. V. A., Vitoriano, B. F., Melo, M. M. D. L., Sampaio, L. R., Borges, D. D. P., Magalhães, S. M. M., & Pinheiro, R. F. (2021) · Medical Oncology · doi:10.1007/s12032-021-01466-1 · Cited by 12 · see citing works

The role of innate immunity in MDS pathogenesis

Sallman, D. A., & List, A. F. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000217 · Cited by 4 · see citing works

The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype

Basiorka, A. A., McGraw, K. L., Eksioglu, E. A., Chen, X., Johnson, J., Zhang, L., Zhang, Q., Irvine, B. A., Cluzeau, T., Sallman, D. A., et al. (2016) · Blood · doi:10.1182/blood-2016-07-730556 · Cited by 356 · see citing works

Changing the Pathobiological Paradigm in Myelodysplastic Syndromes: The NLRP3 Inflammasome Drives the MDS Phenotype

Basiorka, A. A. (2017) · Digital Commons - University of South Florida (University of South Florida)

Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype

Sallman, D. A., Cluzeau, T., Basiorka, A. A., & List, A. F. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00151 · Cited by 115 · see citing works

The NLRP3 Inflammasome as a Driver of the MDS Phenotype

List, A. F. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.08.040